Proscia Inc., a Baltimore-based health technology start-up, announced the addition Monday of new image analysis tools for its cloud-based cancer pathology database.
The company, founded by recent graduates of Johns Hopkins University, aims to significantly improve cancer diagnosis and research with the digital analysis of tissue samples.
"Quantitative image analysis is at the cutting edge of cancer research," said David West, CEO of Proscia, in the announcement.
The announcement was made at the Digital Pathology Association's Pathology Visions conference in San Diego.
Proscia said its system allows for faster and less costly analysis of a tissue sample by digitally comparing it to an array of similar samples. The system is capable of spotting minute differences that may not be observable by the human eye.
The firm aims to partner with academic medical centers, research organizations and biopharmaceutical companies to put its pathology database to use in the fight against cancer.
In July, Proscia received $1 million in seed funding from a group of venture capital investors led by Emerald Development Managers. Other participants included Robin Hood Ventures, TCP Venture Capital and A-Level Capital.
"They have a compelling pipeline of pathology solutions which will undoubtedly advance cancer diagnosis and treatment," said Emerald Development's Neil Cohen in a statement at the time.